PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
mTOR inhibition with rapamycin induces a diabetes-like syndrome characterized by severe glucose intolerance, hyperinsulinemia, and hypertriglyceridemia, which is due to increased hepatic glucose production as well as reduced skeletal muscle glucose uptake and adipose tissue PPARγ activity. Herein, we tested the hypothesis that pharmacological PPARγ activation attenuates the diabetes-like syndrome associated with chronic mTOR inhibition. Rats treated with the mTOR inhibitor rapamycin (2 mg·kg−1·day−1) in combination or not with the PPARγ ligand rosiglitazone (15 mg·kg−1·day−1) for 15 days were evaluated for insulin secretion, glucose, insulin, and pyruvate tolerance, skeletal muscle and adipose tissue glucose uptake, and insulin signaling. Rosiglitazone corrected fasting hyperglycemia, attenuated the glucose and insulin intolerances, and abolished the increase in fasting plasma insulin and C-peptide levels induced by rapamycin. Surprisingly, rosiglitazone markedly increased the plasma insulin and C-peptide responses to refeeding in rapamycin-treated rats. Furthermore, rosiglitazone partially attenuated rapamycin-induced gluconeogenesis, as evidenced by the improved pyruvate tolerance and reduced mRNA levels of phospho enolpyruvate carboxykinase and glucose-6-phosphatase. Rosiglitazone also restored insulin's ability to stimulate glucose uptake and its incorporation into glycogen in skeletal muscle of rapamycin-treated rats, which was associated with normalization of Akt Ser 473 phosphorylation. However, the rapamycin-mediated impairments of adipose tissue glucose uptake and incorporation into triacylglycerol were unaffected by rosiglitazone. Our findings indicate that PPARγ activation ameliorates some of the disturbances in glucose homeostasis and insulin action associated with chronic rapamycin treatment by reducing gluconeogenesis and insulin secretion and restoring muscle insulin signaling and glucose uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677 · cited 1×
“With regards to the latter, there is compelling evidence indicating that obesity-induced mTORC1 overactivation in liver, skeletal muscle, and fat is a crucial event in the development of obesity associated insulin resistance (18, 37, 41).”
BackgroundInsulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 1×
“Indeed, chronic mTORC1 overactivation is a major phenotype found in pathological conditions such as tuberous sclerosis complex disease (17), many types of cancer (29), obesity, and type 2 diabetes (18, 40).”
BackgroundRapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1
Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D. (2013) · Science · doi:10.1126/science.1228792 · Cited by 739
Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1
Um, S. H., D'Alessio, D., & Thomas, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.003 · Cited by 690
Khamzina, L., Veilleux, A., Bergeron, S., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0921 · Cited by 562 · cited 2×
“Indeed, chronic mTORC1 overactivation is a major phenotype found in pathological conditions such as tuberous sclerosis complex disease (17), many types of cancer (29), obesity, and type 2 diabetes (18, 40).”
BackgroundSelf-citationTremblay, F., Brûlé, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X. J., Krebs, M., Polakiewicz, R. D., Thomas, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706517104 · Cited by 465 · cited 2×
“Surprisingly, prolonged rapamycin treatment induces insulin resistance despite inhibiting mTORC1 and alleviating S6K-mediated negative feedback on IRS-1 function (16, 37, 42) in part due to mTORC2 inhibition and reduced Akt/PKB phosphorylation (21, 43).”
BackgroundSelf-citationHoude, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456
Self-citationInsulin resistance in soleus muscle from obese Zucker rats. Involvement of several defective sites
Crettaz, M., Prentki, M., Zaninetti, D., & Jeanrenaud, B. (1980) · Biochemical Journal · doi:10.1042/bj1860525 · Cited by 311
Cited by
Strong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., Fernandez, E., Flurkey, K., Hamilton, K. L., Lamming, D. W., et al. (2016) · Aging Cell · doi:10.1111/acel.12496 · Cited by 362
“…that regulate glucose homeostasis, including the PPARc activator rosiglitazone, might also synergize with rapamycin; rosiglitazone was recently shown to normalize fasting hyperglycemia and attenuate rapamycin-induced glucose intolerance and insulin resistance in rats (Festuccia et al., 2014).”
BackgroundPost-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
Liu, Y., Diaz, V., Fernandez, E., Strong, R., Ye, L., Baur, J. A., Lamming, D. W., Richardson, A., & Salmon, A. B. (2014) · Aging · doi:10.18632/aging.100688 · Cited by 68
“recently showed that rosiglitazone reduces hyperglycemia, glucose intolerance and insulin resistance caused by short-term treatment of rapamycin in rats [29].”
Background
Metadata
- Authors
- Festuccia, W. T., Blanchard, P.-G., Belchior, T., Chimin, P., Paschoal, V. A., Magdalon, J., Hirabara, S. M., Simões, D., St-Pierre, P., Carpinelli, A., Marette, A., & Deshaies, Y.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2014-05-01
- Volume
- 306
- Issue
- 9
- Pages
- E1046-E1054
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2050984746
- Cited by
- 46
- References
- 11
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats. https://app.cochat.ai/papers/10.1152/ajpendo.00683.2013
- The paper
- Festuccia, W. T., Blanchard, P.-G., Belchior, T., Chimin, P., Paschoal, V. A., Magdalon, J., Hirabara, S. M., Simões, D., St-Pierre, P., Carpinelli, A., Marette, A., & Deshaies, Y. (2014). PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00683.2013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.